文献速递儿科影像神经技术与安全MR

儿童钆基对比剂的应用

Gadolinium-based contrast agents in children.
PubMed 文献 · Pediatr Radiol · 2018-08-04

本文综述钆基对比剂(GBCAs)在小儿影像中的应用与潜在风险。GBCAs使用广泛,不良反应风险很低,但肾源性系统性纤维化(NSF)发现后,人们认识到钆可沉积于全身包括脑部,在肾功能正常者的非增强T1加权MR图像上可见。钆沉积的临床效应尚不明确,可能并不存在。作者以历史背景和小儿放射科医生视角提供全面更新。

要点

  • GBCAs不良反应风险很低,但钆可在全身沉积,包括脑部。
  • 肾功能正常者脑部钆沉积可在非增强T1加权MR图像上显示。
  • 钆沉积的临床效应尚不明确,可能并不存在。

核心结论

  • GBCAs使用广泛且不良反应风险很低,但钆可在全身包括脑部沉积,其临床效应尚不明确且可能并不存在。

研究设计与样本

  • 综述;自GBCAs引入以来已给药超过3亿剂;以历史背景和小儿放射科医生视角进行综述。

关键影像表现/征象

  • 肾功能正常者的脑部钆沉积可在非增强T1加权MR图像上可见。

局限性

  • 钆沉积的临床效应尚不明确,可能并不存在。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Gadolinium-based contrast agents (GBCAs) are widely used in medical imaging, with greater than 300 million doses administered since their introduction. The risk of adverse reactions is very low, and GBCAs were thought to be very safe until the discovery of nephrogenic systemic fibrosis (NSF). Since that time, gadolinium has been found to deposit throughout the body, including the brain, where it is visible on non-contrast T1-weighted MR images in people with normal renal function. The clinical effects of this deposition remain unknown and may not exist. In this review the authors provide a comprehensive update on GBCAs and their potential risks, within a historical context and through the lens of a pediatric radiologist.

来源:Pediatr Radiol,查看原文。版权归原作者所有。

引用

  1. Rozenfeld MN, Podberesky DJ. Gadolinium-based contrast agents in children. Pediatr Radiol. 2018. PMID: 30078039. doi:10.1007/s00247-018-4165-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。